The Journal of Nuclear Medicine - JNM

03/06/2026

The Illustrated Post: Isolated occipital lobe hypometabolism on ¹⁸F-FDG PET. https://doi.org/10.2967/jnumed.125.271677

03/05/2026

Advancing theranostics in : FDA approval of beta-amyloid PET drugs for selection of patients for beta-amyloid-directed therapies and other labeling updates. https://ow.ly/OQnS50YmVzx

03/04/2026

What is the reliability and practicability of FAP-RADS Version 1.0 for structured reporting of FAPI imaging in pulmonary and urothelial carcinoma? https://ow.ly/qI2850YmVxK

03/03/2026

Mutations in certain genes are associated with worse survival outcomes among patients treated with Lu-PSMA; this suggests a role for more intensive surveillance to capture early progression. https://ow.ly/fj7s50YmVv4

03/02/2026

Long-term follow-up confirms the favorable safety profile of ⁹⁰Y-FAPI-46 therapy in patients with metastatic sarcoma. https://ow.ly/4UHH50YmVqa

02/27/2026

Clinical correlation no longer required: An LLM practical use scenario in PET reporting. https://ow.ly/mBcu50Yng8f

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

02/27/2026

Can total-body PET network analysis be used to characterize immune response with multiorgan involvement, to better diagnose, prognose, and treat patients? https://ow.ly/QyhV50YiTRe

02/26/2026

The combination of ²¹¹At-hCD20 radioimmunotherapy and immune checkpoint inhibitors acts in synergy to attack both hCD20(+) and hCD20(–) tumor cells in immunocompetent mice. https://ow.ly/FAUY50YiTEo

02/25/2026

In a highly vulnerable patient population, pretreatment PSMA-targeted PET imaging can support personalized treatment, helping to identify those most likely to benefit from ²²⁵Ac-PSMA-I&T . https://ow.ly/URXt50YiTpL

02/24/2026

²⁰³Pb-VMT-α-NET appears safe and effective for single-photon imaging of SSTR2-positive , and the ²⁰³Pb/²¹²Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm. https://ow.ly/36IL50YiTg9

02/23/2026

¹⁸F-SynVesT-1 PET imaging provides a sensitive, noninvasive measure of SV2A loss after and can discriminate between different levels of injury severity. https://ow.ly/BNjk50YiT2B

02/20/2026

Improved PET and CT alignment across a range of distinct distributed tracers reduces dose PET and CT protocols without compromising quantification accuracy. https://ow.ly/VTN850YiSzK